Trial Profile
Open Label Study of the Anti Insulin-like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent (Dose Escalation, Part 1) and in Combination With Velcade (Combination, Part 2) in Patients With Recurrent, Refractory Multiple Myeloma (MM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs VRDN 001 (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Sanofi
- 13 Dec 2007 New trial record.